Phase 2 data for hot flash antibody ABCL635 showed an 83% reduction in frequency versus 33% on placebo, enough to pull in an oversubscribed $200 million raise. Operating costs fell hard, narrowing the net loss to $40.8 million from $57.1 million a year ago. Twelve-week data lands in early 2027.
Latest Activity
ABCL Coverage
7 Healthcare AI Stocks Under $50 With Huge Upside Potential
Healthcare AI stocks have been hammered in 2026, with several names down 30% to 65% year to date even as their underlying platforms keep maturing. That dislocation between share price and product…
5 Penny Stocks With 250% Upside in 1 Year According to Wall Street
Penny stocks represent an interesting investment opportunity. These stocks typically represent small companies or companies that are early in the development stages. But isn’t that how you make it big in the…